SEC Seeks Entry Of Judgment For $30M EpiPen Classification Settlement
WASHINGTON, D.C. — Mylan N.V. will pay $30 million to settle claims brought by the Securities and Exchange Commission alleging that the pharmaceutical company misclassified its EpiPen epinephrine autoinjector as a...To view the full article, register now.
Already a subscriber? Click here to view full article